Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns (NCT06551220)

🧪 Interventions in This Study

• Trastuzumab Deruxtecan (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (26 Sites)

Showing the first 25 of 26 sites.

• Yale Cancer Center — New Haven, Connecticut
• Dana-Farber Cancer Institute, Harvard Medical School — Boston, Massachusetts
• Fujian Cancer Hospital, Fujian Medical University — Fuzhou, Fujian
• The 10th Affiliated Hospital of Southern Medical University — Dongguan, Guangdong
• The First People's Hospital of Foshan — Foshan, Guangdong
• The Sixth Affiliated Hospital, School of Medicine, South China University of Technology. — Foshan, Guangdong
• Sun Yat-sen University Cancer Center — Guangzhou, Guangdong
• The Affiliated Panyu Central Hospital, Guangzhou Medical University — Guangzhou, Guangdong
• Guangdong Provincial Hospital of Chinese Medicine — Guangzhou, Guangdong
• The Affiliated Cancer Hospital, Guangzhou Medical University — Guangzhou, Guangdong
• The First Affiliated Hospital of Guangzhou Medical University — Guangzhou, Guangdong
• The First Affiliated Hospital of Guangzhou University of Chinese Medicine — Guangzhou, Guangdong
• Cancer Hospital of Shantou University Medical College — Shantou, Guangdong
• Yuebei People's Hospital of Shantou University — Shaoguan, Guangdong
• National Cancer Center Shenzhen Hospital — Shenzhen, Guangdong
• Shenzhen People's Hospital — Shenzhen, Guangdong
• Zhongshan City People's Hospital — Zhongshan, Guangdong
• The Fifth Affiliated Hospital of Sun Yat-sen University — Zhuhai, Guangdong
• Changde Hospital, Xiangya School of Medicine, Central South University — Changde, Hunan
• Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University — Changsha, Hunan
• The Second Xiangya Hospital of Central South University — Changsha, Hunan
• The First Affiliated Hospital, Hengyang Medical School, University of South China — Hengyang, Hunan
• Affiliated Cancer Hospital of Inner Mongolia Medical University — Hohhot, Inner Mongolia
• The First Affiliated Hospital of Nanjing Medical University — Nanjing, Jiangsu
• Xinhua Hospital Afliated to Shanghai Jiaotong University — Shanghai, Shanghai Municipality

📞 Contact the Study Coordinator

Phone: 86-020-87343806

Email: xiexm@sysucc.org.cn

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Breast Cancer

• Assessing the Time Demands of Cancer — Birmingham, Alabama
• Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer — Birmingham, Alabama
• A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer — Commack, New York
• Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor — Washington D.C., District of Columbia
• A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer — Tucson, Arizona
• Roll-over Study to Allow Continued Access to Ribociclib — Chandler, Arizona

Explore by condition: All Metastatic Breast Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.